Boston Millennia Partners IV is pleased to announce its investment in Reveleer, Inc. as part of a growth equity financing round. Reveleer is a healthcare software and services company that empowers health insurance companies to take control of their risk adjustment and quality improvement programs. The Reveleer software platform enables insurers to independently execute and manage every aspect of provider outreach, health record retrieval, coding, abstraction, and reporting. Leveraging its technology, proprietary data sets, and subject matter expertise, Reveleer also provides record retrieval and review services to support financial performance and improved member outcomes. As value-based contracts expand and the Medicare Advantage population continues to grow, the company is well positioned to be a leader in risk adjustment and quality analysis software. Click below to read on.
Read Full Release
When you go to your doctor's office, sometimes it seems the caregivers spend more time gathering data about you than treating you as a patient. Electronic medical records are everywhere – annoying to doctors and intrusive to patients. But now researchers are looking to see if they can plow through the vast amount of data that's gathered in those records, along with insurance billing information, to tease out the bits that could be useful in refining treatments and identifying new uses for drugs.
Read Full Release
Over the years oncologists and health care experts have struggled to find new ways to reduce the cost of cancer treatment. The American Cancer Society estimates patients paid nearly $4 billion in out-of-pocket costs in 2014, and that the disease cost the country around $88 billion in cancer-related health care spending that same year. Some doctors are now looking at emerging oncology data companies to help reduce that financial burden all while improving clinical outcomes.
Read Full Release
Durham, North Carolina and Sofia, Bulgaria. Health Decisions, Inc., the leading US full-service women’s health specialty CRO and Comac Medical, a full-service CRO/SMO operating in 24 European countries, today announced an expansion of their strategic alliance to conduct women’s health clinical trials in the United States, Western and Central and Eastern Europe.
“Health Decisions is pleased to strengthen its strategic women’s health alliance with our colleagues at Comac Medical,” stated Health Decisions’ Chief Executive Officer Patrick Phillips, BSc (Hons), D.Phil. “The Health Decisions/Comac Medical alliance provides sponsors of women’s health trials with extensive therapeutic and operational expertise and access to hundreds of investigational women’s health sites in the United States and Europe. These regions provide care for hundreds of millions of women and generate approximately two-thirds of the revenues of the global biopharmaceutical industry. This strategic alliance will enable Health Decisions to fulfill its mission of improving healthcare outcomes for women worldwide and assisting sponsors who share that goal.”
Read Full Release
Cota Inc., a real-world data and analytics company bridging precision medicine to population health, today announced its founder and executive chairman, Andrew Pecora, M.D., will speak today, April 27 at the Fourth International Vatican Conference, Unite to Cure: A Global Health Care Initiative, which is being held from April 26-28 at the Aula Nuova del Sinodo in Vatican City. The event will build on the current global health care movement and unite world leaders across all disciplines to engage in powerful conversations about how science, technology and 21st century medicine will impact culture and society.
Read Full Release
On this episode we talk with Stuart Goldberg, MD, Chief Scientific Officer at Cota. Dr. Goldberg tells us all about Cota’s physician-led journey to organize and classify real-world evidence about every type of cancer. This effort led to something they call the Cota Nodal Address (CNA), and it’s enabling health systems to get very specific about the types of patients they’re treating, the costs associated with them, and the outcomes being achieved. This apples-to-apples comparison allows Cota to identify variation and address it in ways that are beneficial to the provider, payer and patient. It enables a concept Dr. Goldberg calls “Precision Payment”, which in turn enables proper bundled payment design, and precision medicine.
Read Full Release
First, given that (as Andrew Matzkin of Health Advances observed) the Flatiron transaction is “putting smiles on a lot of faces,” what other emerging oncology clinical data companies might soon be in play? And second, more fundamentally, what are the implications of the rise of these types of companies – for both pharma and for healthcare?
Read Full Release
Cota Inc., a healthcare real-world evidence and data analytics company bridging precision medicine to population health, today announced the completion of a Series C round of financing led by IQVIA (NYSE: IQV) with major participation by EW Healthcare Partners.
Cota will leverage this funding to scale its solutions across healthcare providers, payers and life sciences companies. The funding will also advance its proprietary Cota Nodal Address™ (CNA) system, a powerful and unique precision disease classification system built on its comprehensive real-world data set. Memorial Sloan Kettering Cancer Center also participated in the round, along with existing Cota investors which include, Boston Millennia Partners, Horizon Blue Cross Blue Shield of New Jersey, Hackensack Meridian Health and Atoc Holdings.
Read Full Release
For the seventh time in eight years, MedAptus® has been named the Category Leader in the Mobile Charge Capture segment in the “2018 Best in KLAS Awards: Software & Services” report. The award recognizes the performance of its CHARGE PRO software product, a charge capture, management and reconciliation that improves financial performance for physicians and hospitals by accurately converting billable services into ICD-10 codes quickly and easily. The company’s top-ranking score of 91.9 reflects feedback from customers across measures evaluating vendor performance data and overall satisfaction.
Read Full Release
